PFE - Pfizer Inc.
35.83 0.00 (0.00%)
After hours: 4:58PM EDT
| Previous Close | 36.20 |
| Open | 36.25 |
| Bid | 35.79 x 500 |
| Ask | 35.99 x 300 |
| Day's Range | 35.79 - 36.29 |
| 52 Week Range | 29.83 - 36.60 |
| Volume | 14,417,647 |
| Avg. Volume | 17,060,540 |
| Market Cap | 213.09B |
| Beta | 1.09 |
| PE Ratio (TTM) | 26.21 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.28 (3.52%) |
| Ex-Dividend Date | 2017-11-09 |
| 1y Target Est | N/A |
- CNBC Videos•yesterday
This hot trade is about to get even hotter: Trader
The “Fast Money” traders discuss the health care sector seeing a pop and where it could go from here.
- Zacks•54 minutes ago
What to Expect from Big Pharmas After J&J's Solid Q3 Results?
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
- Motley Fool•4 hours ago
Here's Why Ignyta Stock Soared as Much as 27.5% Today
The biopharma's lead drug candidate has strong potential based on a sneak peek at midstage trial data.
InvestorPlace•5 hours agoDow Jones Industrial Average Hits 23,000. Now What?
On Oct. 18, the Dow Jones Industrial Average hit a new all-time intraday high of 23,145 as of this writing. Investors who aren’t playing the indices can gain exposure to the Dow Jones today through the SPDR Dow Jones Industrial Average ETF (NYSEARCA:DIA). With the index up 16.3% in 2017, though, how much longer can this rally continue?
Reuters•7 hours agoReckitt to reshape as sales growth evaporates
Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. It hopes to improve performance in its newly expanded health business, while bringing greater focus and accountability to its slower-growth home and hygiene business. Reckitt, whose products range from Durex condoms to Lysol disinfectant, has blamed fallout from a cyber attack, a failed product launch and a safety scandal in South Korea for its lacklustre sales.
- Financial Times•8 hours ago
[$$] Reckitt Benckiser: fission for compliments
In the physics of business, the entropic forces that break down a system can also liberate energy. Hidden value is meant to be released from spin-offs and the like, especially when profit growth slows. ...
- The Wall Street Journal•8 hours ago
[$$] Reckitt Makeover Clears Way for Pfizer Bid
The London-listed consumer group is doing what activist Nelson Peltz wants Procter & Gamble to do—but M&A may be an ulterior motive.
- Reuters•9 hours ago
Reckitt to reshape as sales growth evaporates
Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. The change follows ...
- Bloomberg•10 hours ago
Pfizer's Advil May Be Just the Thing for Sickly Reckitt
The problem is getting shareholders to back a cash call to pay for it.
- Reuters•15 hours ago
Reckitt Benckiser to form two business units for better focus
Reckitt Benckiser (RB.L) plans to reorganise its business into two distinct units, one for health and the other for hygiene and home products, as it tries to improve its flagging performance. The maker of Durex condoms, Nurofen tablets and Dettol cleaners announced the restructuring on Wednesday, along with its third-quarter sales figures. The British company made the decision to restructure after its June acquisition of U.S. baby formula maker Mead Johnson, which will account for roughly half of the larger health unit's sales.
- Bloomberg•15 hours ago
Reckitt CEO Focuses on Health, Looking Beyond Worst Year
Reckitt Benckiser Group Plc separated its home-care and health businesses, sharpening its focus on brands such as Durex condoms and Enfamil baby formula after a second cut in the sales forecast this year....
- Forbes•18 hours ago
Tiny Ignyta's Lung Cancer Drug Bested Pfizer's. Probably. Will We Ever Know For Sure?
Results of a 32-patient study of a drug made by Ignyta Pharmaceuticals, a San Diego-based drugmaker, are a best case scenario for the company. The drug shrank tumors in 79% of patients and kept workingabout 10 months longer than the current drug, Pfizer’s Xalkori, did in earlier clinical trials.
- Zacks•23 hours ago
Aerie (AERI) Up on FDA Review Committee Result for Rhopressa
Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.
- Zacks•yesterday
J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales
J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.
- Zacks•yesterday
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
- Forbes•yesterday
The Blockbuster That Wasn't -- A CETP Inhibitor Post-Mortem
The quest for the “holy grail” of cardiovascular therapy - a drug that dramatically lowered LDL-c and raised HDL-c and which would hopefully reverse atherosclerosis - has ended ignominiously.
- Investopedia•2 days ago
How Stock Investors Can Profit Big From Spinoffs
Spinning Rich Profits: Spinoffs as a group have posted total returns of nearly 300% over 10 years
- Forbes•2 days ago
The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
- The Wall Street Journal•2 days ago
[$$] Drugstore Favorites May Be Catching the Common Consumer Cold
Customers may be starting to shop for over-the-counter drugs in the same way they shop for groceries—with a keener eye for cost and content—and this could be painful for consumer-health companies.
- TheStreet.com•3 days ago
Pfizer Consumer Unit Worth as Much as $14 Billion
A deal would give the company capital to do more deals but the decision also keeps the company's recently scratched plans to split into two separate companies alive. The division itself had about $3.4 ...
- Motley Fool•5 days ago
Earnings Season Preview: 2 Things to Watch For in Healthcare
J&J is the lead-off hitter, and its Remicade results will tell us a lot. So will the biosimilar numbers from Pfizer.
- Motley Fool•5 days ago
Pfizer Says It's Pondering a Big Sale
The pharmaceutical major announced it's thinking about finding a buyer for its consumer healthcare unit.
- Zacks•5 days ago
5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
The pharma/biotech sector has a number of things going in its favor.
- Zacks•5 days ago
Spin-Off ETF: Can the Outperformance Continue?
Spin-off activities picked up pace in the United States.
